Arab Abdulmalik Zuhair, Conti Aldo Alberto, Davey Fleur, Khan Faisel, Baldacchino Alexander Mario
Division of Systems Medicine, School of Medicine, University of Dundee, Dundee, United Kingdom.
Division of Population and Behavioural Science, School of Medicine, University of St Andrews, St Andrews, United Kingdom.
Front Pharmacol. 2021 Nov 5;12:725034. doi: 10.3389/fphar.2021.725034. eCollection 2021.
In 2019, Scotland reported the highest number of drug deaths amongst EU countries. Of the 1,264 drug deaths reported in 2019, 94% were related to polysedative use. Studies have proposed a relationship between opioid use and cardiovascular disease. Furthermore, the concomitant use of sedatives and opioids has been associated with lethal cardiopulmonary events. However, evidence is still limited for the relationship between polysedative use and cardiovascular diseases. Thus, the present study aimed to investigate the association between polysedative use and the underlying cardiovascular pathologies in drug deaths. This study consisted of a post-mortem investigation of 436 drug deaths. Data extracted from post-mortem reports included socio-demographic characteristics (e.g., gender, age), cardiovascular pathologies (e.g., atherosclerosis, atheroma, and inflammation), in addition to the presence of opioids (e.g. methadone, heroin) and other substances (e.g., alcohol, benzodiazepine) in the blood of the deceased. Stepwise multiple regression models were employed to identify which substances predicted cardiovascular pathologies. The presence of opioids, benzodiazepines, and alcohol in the blood of the deceased predicted overall cardiovascular disease (CVD) severity [R2 = 0.33, F (5, 430) = 39.64, < 0.0001; adjusted R2 = 0.32, f2 = 0.49]. Positive Beta coefficients may indicate an exacerbation of CVD (B = 0.48 95% CI = 0.25, 0.70) due to the presence of opioids in the blood of the deceased. Negative associations may instead indicate a relative protective effect of alcohol (B = -0.2, 95% CI = -0.41, -0.00) and benzodiazepines (B = -0.29, 95% CI = -0.48, -0.09) on CVD. These findings may inform national clinical guidelines on the need to monitor individuals who abuse opioids for presence of cardiovascular disease risk factors pathologies and provide timely interventions to reduce mortality in the population.
2019年,苏格兰报告的药物致死人数在欧盟国家中位居榜首。在2019年报告的1264例药物致死案例中,94%与多药并用(同时使用多种镇静剂)有关。研究表明阿片类药物的使用与心血管疾病之间存在关联。此外,镇静剂和阿片类药物的同时使用与致命的心肺事件有关。然而,关于多药并用与心血管疾病之间的关系,证据仍然有限。因此,本研究旨在调查多药并用与药物致死中潜在的心血管病理之间的关联。这项研究包括对436例药物致死案例进行尸检调查。从尸检报告中提取的数据包括社会人口统计学特征(如性别、年龄)、心血管病理(如动脉粥样硬化、动脉粥样瘤和炎症),以及死者血液中阿片类药物(如美沙酮、海洛因)和其他物质(如酒精、苯二氮䓬)的存在情况。采用逐步多元回归模型来确定哪些物质可预测心血管病理。死者血液中阿片类药物、苯二氮䓬和酒精的存在可预测总体心血管疾病(CVD)严重程度[R2 = 0.33,F(5, 430) = 39.64,< 0.0001;调整后R2 = 0.32,f2 = 0.49]。正的β系数可能表明由于死者血液中存在阿片类药物,CVD病情加重(B = 0.48,95%置信区间 = 0.25, 0.70)。相反,负相关可能表明酒精(B = -0.2,95%置信区间 = -0.41, -0.00)和苯二氮䓬(B = -0.29,95%置信区间 = -0.48, -0.09)对CVD有相对保护作用。这些发现可能为国家临床指南提供参考,以了解监测滥用阿片类药物的个体是否存在心血管疾病风险因素病理的必要性,并及时进行干预以降低人群死亡率。